<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940830-2-00058</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=94 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=50 g=1 f=1 -->   <USDEPT>DEPARTMENT OF HEALTH AND HUMAN SERVICES</USDEPT>  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 -->  <USBUREAU>Food and Drug Administration</USBUREAU> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 --> Notice of Intent to Award A Grant with Time Constraints <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Food and Drug Administration, HHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Notice. <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> The Food and Drug Administration (FDA) is announcing its intention to accept and consider an application for the award of a grant with time constraints to the American Drug Development, Inc. (ADD). The purpose of the grant is to provide the orphan drug, Sodium Phenylbutyrate, to children with three urea cycle disorders (deficiencies of carbamyl phosphate synthetase, ornithine transcarbamylase (OTC), and argininosuccinic acid synthetase) which, if not treated, are fatal to the patient. Competition is limited to ADD because ADD is the entity currently able to manufacture and supply Sodium Phenylbutyrate for the treatment of these disorders. ADD is also in the process of compiling documentation which will be submitted to FDA for approval of a new drug application (NDA) for Sodium Phenylbutyrate. Until the NDA is approved, this drug is not available to patients by any other means other than through a grant to ADD. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </SUMMARY> <ADDRESS> <!-- PJG ITAG l=10 g=1 f=2 --> ADDRESSEES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> An application form is available from, and completed applications should be submitted to: Maura C. Stephanos, Office of Contracts and Grants Management (HFA&hyph;520), Food and Drug Administration, Park Bldg., rm. 3&hyph;40, 5600 Fishers Lane, Rockville, MD 20857, 301&hyph;443&hyph;6170.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> NOTE: Applications hand-carried or commercially delivered should be addressed to the Park Bldg., rm. 3&hyph;40, 12420 Parklawn Dr., Rockville, MD 20857. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </ADDRESS> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT:  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=14 g=1 f=2 --> Regarding the administrative and financial management aspects of this notice: Maura C. Stephanos (address above). <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=14 g=1 f=2 --> Regarding the programmatic aspects of this notice: Carol A. Wetmore, Office of Orphan Products Development (HF&hyph;35), Food and Drug Administration, 5600 Fishers Lane, rm. 8&hyph;73, Rockville, MD 20857, 301&hyph;443&hyph;4903. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> FDA is announcing its intention to accept and consider an application for the award of a grant with time constraints to ADD, Baltimore, MD. FDA's authority to enter into grants for the development of drugs for rare diseases and conditions is set out in Section 5 of the Orphan Drug Act (21 U.S.C. 360ee). FDA's research program is described in the Catalog of Federal Domestic Assistance No. 93.103. Before entering into grants, FDA carefully considers the benefits that such grants will provide to the public. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ADD's application will undergo a peer review in accordance with the Public Health Service policies and procedures governing the review of grant applications with time constraints. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> I. Background  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> For the past 8 years, FDA's Office of Orphan Products Development (OPD) has funded a clinical research grant for the treatment of urea cycle disorders with Sodium Phenylbutyrate. This grant expires September 30, 1994. Due to the life-threatening nature of urea cycle disorders, it is necessary to have a 3-month supply of the drug on hand in case possible problems in the purity and/or availability of the drug arise. For this reason, more drugs must be ordered by September 15, 1994, to ensure an adequate drug supply. ADD is able to immediately manufacture and supply the drug for the treatment of these disorders. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> II. Mechanism of Support <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 --> A. Award Instrument <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Support will be in the form of a grant. In 1994, the FDA estimate for this grant award is $ 750,000 (final amount will be negotiated). The award will be subject to all policies and requirements that govern the research grant programs of the Public Health Service (PHS), including the provision of 42 CFR part 52, 45 CFR part 74, and the PHS grants policy statement. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 --> B. Length of Support <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The length of support may be for 24 months with no possibility of additional noncompetitive support.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> III. Reasons for Award With Time Constraints <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> FDA believes that there is a compelling need to award a grant to ADD based on time constraints because these urea cycle disorders are fatal if untreated. Also, FDA believes that ADD is uniquely qualified to fulfill the objectives of the proposed grant because it is able to immediately manufacture and supply Sodium Phenylbutyrate. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> IV. Reporting Requirements <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Program progress reports and financial status reports will be required annually, based on the date of award. These reports will be due within 30 days after the end of the budget period. A final program progress report and financial status report will be due 90 days after expiration of the project period of the grant. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> V. Smoke-Free Workplace <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> PHS strongly encourages all grant recipients to provide a smoke-free workplace and promote the nonuse of all tobacco products. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: August 24, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> William K. Hubbard, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Interim Deputy Commissioner for Policy. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;21281 Filed 8&hyph;29&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4160&hyph;01&hyph;F <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            